

S1 Table. Patient characteristics of study population

Characteristic	No. of patients (%) (n=1,181)
Age (yr)	
< 45	382 (32)
≥ 45	799 (68)
Menopausal status	
Premenopausal	726 (61)
Peri- or postmenopausal	455 (39)
Molecular subtype	
Luminal A	446 (38)
Luminal B	384 (33)
HER2	123 (10)
Triple negative	228 (19)
T category	
T1	615 (52)
T2	428 (36)
T3	102 (9)
T4	36 (3)
N category	
N0	652 (55)
N1	286 (24)
N2	159 (14)
N3	84 (7)
AJCC stage	
I	497 (42)
II	396 (34)
III	288 (24)
Histologic grade	
I-II	665 (56)
III	379 (32)
Unknown	137 (12)
Lymphovascular invasion	
No	600 (51)
Yes	425 (36)
Unknown	156 (13)
Primary surgery	
Breast-conserving	936 (79)
Mastectomy	245 (21)
Lymph node surgery	
No ALND	637 (54)
ALND	544 (46)
Chemotherapy	
No	253 (21)
Yes	928 (79)

HER2, human epidermal growth factor receptor 2; AJCC, American Joint Committee on Cancer; ALND, axillary lymph node dissection.